Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.

Plain-language guide to PMID 18753120 (2008): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 18753120
Journal: HIV clinical trials
Year: 2008
Study type: Randomized Controlled Trial
Authors: Macallan DC et al. (7 authors)
DOI: 10.1310/hct0904-254

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Treatment options for HIV-associated lipodystrophy syndrome (HALS) remain limited.

The objective of this randomized open-label study was to compare three emerging therapies, rosiglitazone, pravastatin, and growth hormone alone and together, in men and women with HALS.

Who Took Part

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and pilot study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

Primary endpoint was body composition change by dual X-ray absorptiometry (DXA) and computed tomography (CT).

What Was Measured

PubMed files the paper under topics including Absorptiometry, Photon, Body Composition, Endpoint Determination, Fats, HIV-1, HIV-Associated Lipodystrophy Syndrome and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized, open-label and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (HIV clinical trials), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.